Day One Biopharmaceuticals, Inc. (DAWN): History, Ownership, Mission, How It Works & Makes Money

Ever wonder how a biopharmaceutical company navigates the complex world of cancer treatment, especially for children? Day One Biopharmaceuticals, Inc. (DAWN) is dedicated to developing and commercializing targeted therapies for patients of all ages with genetically defined cancers, with a strong focus on pediatric patients. With the FDA approval and commercial success of OJEMDA, generating over $57 million in net product revenues in 2024, and ending the year with over $500 million in cash, how does Day One Biopharmaceuticals operate and generate revenue, and what's their mission? Keep reading to find out!

Day One Biopharmaceuticals, Inc. (DAWN) History

[Company's] Founding Timeline

Year established

Day One Biopharmaceuticals was established in 2018.

Original location

The company is based in South San Francisco, California.

Founding team members

The founding team includes:

• Dr. Julieக்கூ, Chief Executive Officer
• Dr. Pablo Lee, Chief Scientific Officer

Initial capital/funding

Day One Biopharmaceuticals launched with a Series A financing of $60 million led by Kleiner Perkins in 2019.

[Company's] Evolution Milestones

[Company's] Transformative Moments

• 2019: Series A Funding: This initial funding of $60 million provided the capital necessary to advance their research and development programs, laying the groundwork for future clinical trials and expansion.
• 2020: Series B Funding: The $130 million Series B funding significantly boosted Day One’s capabilities, enabling them to aggressively pursue clinical trials and broaden their therapeutic pipeline, marking a pivotal moment in their growth trajectory.
• 2023: Breakthrough Therapy Designation: The FDA's decision to grant Breakthrough Therapy Designation for Tovorafenib underscored the drug's potential to address a critical unmet need in pediatric low-grade glioma, enhancing its profile and expediting its development pathway.
• 2024: FDA Approval of Ojemda (tovorafenib): The FDA approval of Ojemda represented a monumental achievement, validating years of research and development efforts. This milestone not only provided a new treatment option for patients with relapsed or progressive low-grade glioma but also positioned the company as a leader in pediatric oncology therapeutics.

To gain more insights into the values that drive the company, explore Mission Statement, Vision, & Core Values of Day One Biopharmaceuticals, Inc. (DAWN).

Day One Biopharmaceuticals, Inc. (DAWN) Ownership Structure

Day One Biopharmaceuticals, Inc. operates with a mixed ownership structure, encompassing institutional, insider, and public shareholders.

Day One Biopharmaceuticals, Inc.'s Current Status

Day One Biopharmaceuticals, Inc. is a public company, trading on the NASDAQ Global Select Market under the ticker symbol DAWN.

Day One Biopharmaceuticals, Inc.'s Ownership Breakdown

Understanding the ownership structure of Day One Biopharmaceuticals can provide insights into the company's governance and strategic direction. Here's a breakdown of the ownership composition:

Day One Biopharmaceuticals, Inc.'s Leadership

The leadership team is crucial to the strategic direction and operational execution of Day One Biopharmaceuticals, Inc. Key figures include:

• Jeremy Bender: Chief Executive Officer
• Sarah Larson: Chief Commercial Officer
• Sam Blackman: Chief Financial Officer
• Dr. Jennifer Grant: Chief Medical Officer

For more insights into the company's goals, see Mission Statement, Vision, & Core Values of Day One Biopharmaceuticals, Inc. (DAWN).

Day One Biopharmaceuticals, Inc. (DAWN) Mission and Values

Day One Biopharmaceuticals is dedicated to developing and commercializing therapies for childhood cancers, reflecting a commitment to addressing unmet needs in pediatric oncology. The company's values likely revolve around innovation, patient-centricity, and collaboration to improve outcomes for children with cancer.

Day One Biopharmaceuticals' Core Purpose

Official mission statement

Day One Biopharmaceuticals' mission statement is: 'To drive new hope for children and families living with cancer.'

Vision statement

While a specific, distinct vision statement might not be explicitly publicized, the vision of Day One Biopharmaceuticals can be inferred from their actions and focus:

• To become a leader in pediatric oncology drug development.
• To significantly improve the survival rates and quality of life for children with cancer.
• To foster a collaborative environment that drives innovation in cancer treatment.

Company slogan/tagline

Day One Biopharmaceuticals' slogan is: 'Every day matters.'

To delve deeper into the financial aspects of the company, explore Breaking Down Day One Biopharmaceuticals, Inc. (DAWN) Financial Health: Key Insights for Investors.

Day One Biopharmaceuticals, Inc. (DAWN) How It Works

Day One Biopharmaceuticals is dedicated to developing and commercializing targeted therapies for cancers that primarily affect children and adolescents.

Day One Biopharmaceuticals, Inc.'s Product/Service Portfolio

Day One Biopharmaceuticals, Inc.'s Operational Framework

Day One Bio operates with a focus on:

• Targeted Therapies: Concentrating on developing drugs that precisely target the genetic drivers of cancer, particularly in pediatric populations.
• Clinical Development: Conducting rigorous clinical trials to evaluate the safety and efficacy of their drug candidates. For example, the company announced positive topline results from the pivotal FIREFLY-1 trial evaluating tovorafenib in pLGG patients.
• Regulatory Approval: Pursuing regulatory approvals from health authorities like the FDA to bring their therapies to market.
• Commercialization: Preparing for the commercial launch of approved products, including manufacturing, distribution, and marketing strategies.

More about Day One Biopharmaceuticals, Inc. you can read here: Mission Statement, Vision, & Core Values of Day One Biopharmaceuticals, Inc. (DAWN).

Day One Biopharmaceuticals, Inc.'s Strategic Advantages

Day One Bio's strategic advantages include:

• Focus on Pediatric Cancer: Addressing a significant unmet need in pediatric oncology.
• Targeted Approach: Developing therapies that target specific genetic mutations, potentially leading to more effective and less toxic treatments.
• Experienced Team: A management team with experience in drug development and commercialization.

Day One Biopharmaceuticals, Inc. (DAWN) How It Makes Money

Day One Biopharmaceuticals, Inc. operates as a commercial-stage biopharmaceutical company, focusing on developing and commercializing therapies for cancers, particularly those affecting children. The company generates revenue primarily through the sale of its approved drug, Tovorafenib (Tovor), which addresses unmet needs in pediatric oncology.

Day One Biopharmaceuticals, Inc.'s Revenue Breakdown

As a commercial-stage biopharmaceutical company with a recently approved product, the revenue streams for Day One Biopharmaceuticals are currently concentrated. The following table provides a breakdown:

Day One Biopharmaceuticals, Inc.'s Business Economics

Day One Biopharmaceuticals, Inc.'s business economics are centered around the development, approval, and commercialization of Tovorafenib (Tovor). Key aspects include:

• Pricing Strategy: The pricing of Tovor is likely based on several factors, including the cost of drug development, the clinical benefit it offers, and the prices of competing therapies.
• Market Access: Securing favorable reimbursement and formulary placement with insurance companies and healthcare providers is crucial. This involves demonstrating the value of Tovor through health economic outcomes research.
• Production and Supply Chain: Efficient manufacturing and distribution are essential to ensure a reliable supply of Tovor to meet patient demand.
• R&D Investments: A significant portion of revenue is reinvested into research and development to expand the pipeline with new therapies and indications.

Day One Biopharmaceuticals, Inc.'s Financial Performance

Given its status as a commercial-stage company, key financial performance indicators for Day One Biopharmaceuticals include:

• Revenue Growth: Monitoring the sales trajectory of Tovor is critical. Initial sales figures and growth rates indicate market uptake and commercial success.
• Gross Margin: The gross margin on Tovor sales reflects the efficiency of production and pricing strategies.
• Operating Expenses: These include R&D expenses, sales and marketing costs, and general and administrative expenses. Managing these costs is essential for achieving profitability.
• Net Income/Loss: As a company focused on growth, Day One Biopharmaceuticals may incur net losses as it invests heavily in R&D and commercialization. The trend in net income/loss provides insights into the company's progress towards profitability.
• Cash Position: A strong cash position is vital to fund ongoing operations and future development programs. Monitoring cash burn rate and runway is important.

To gain further insights into the company's mission, vision, and core values, refer to Mission Statement, Vision, & Core Values of Day One Biopharmaceuticals, Inc. (DAWN).

Day One Biopharmaceuticals, Inc. (DAWN) Market Position & Future Outlook

Day One Biopharmaceuticals is strategically positioned to impact the pediatric oncology market, focusing on developing and commercializing targeted therapies. Their future outlook hinges on the successful development and launch of current pipeline assets and expanding their portfolio to address unmet needs in childhood cancer treatments.

Competitive Landscape

Opportunities & Challenges

Industry Position

Day One Biopharmaceuticals operates within the highly competitive oncology market, specifically targeting pediatric cancers. Given the focus on unmet needs and precision medicine, the company differentiates itself through:

• Targeted Therapies: Development of drugs that address specific genetic mutations in pediatric cancers.
• Niche Market: Focus on a specific segment of the oncology market, allowing for specialized expertise and tailored approaches.
• Innovation: Commitment to novel research and development to bring new treatment options to patients.

To gain deeper insights into the company's guiding principles, explore the Mission Statement, Vision, & Core Values of Day One Biopharmaceuticals, Inc. (DAWN).